BACKGROUND AND PURPOSE: We hypothesized that an in vitro, stretch-based model of neural injury may be useful to identify compounds that decrease the cellular damage in neurotrauma. EXPERIMENTAL APPROACH: We screened three neural cell lines (B35, RN33B and SH-SY5Y) subjected to two differentiation methods and selected all-trans-retinoic acid-differentiated B35 rat neuroblastoma cells subjected to rapid stretch injury, coupled with a subthreshold concentration of H2 O2 , for the screen. The model induced marked alterations in gene expression and proteomic signature of the cells and culminated in delayed cell death (LDH release) and mitochondrial dysfunction [reduced 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) conversion]. Follow-up studies utilized human stem cell-derived neurons subjected to rapid stretch injury. KEY RESULTS: From screening of a composite library of 3500 drugs, five drugs (when applied in a post-treatment regimen relative to stretch injury) improved both LDH and MTT responses. The effects of rifampicin were investigated in further detail. Rifampicin reduced cell necrosis and apoptosis and improved cellular bioenergetics. In a second model (stretch injury in human stem cell-derived neurons), rifampicin pretreatment attenuated LDH release, protected against the loss of neurite length and maintained neuron-specific class III β-tubulin immunoreactivity. CONCLUSIONS AND IMPLICATIONS: We conclude that the current model is suitable for medium-throughput screening to identify compounds with neuroprotective potential. Rifampicin, when applied either in pre- or post-treatment, improves the viability of neurons subjected to stretch injury and protects against neurite loss. Rifampicin may be a candidate for repurposing for the therapy of traumatic brain injury. LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
BACKGROUND AND PURPOSE: We hypothesized that an in vitro, stretch-based model of neural injury may be useful to identify compounds that decrease the cellular damage in neurotrauma. EXPERIMENTAL APPROACH: We screened three neural cell lines (B35, RN33B and SH-SY5Y) subjected to two differentiation methods and selected all-trans-retinoic acid-differentiated B35 ratneuroblastoma cells subjected to rapid stretch injury, coupled with a subthreshold concentration of H2 O2 , for the screen. The model induced marked alterations in gene expression and proteomic signature of the cells and culminated in delayed cell death (LDH release) and mitochondrial dysfunction [reduced 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) conversion]. Follow-up studies utilized human stem cell-derived neurons subjected to rapid stretch injury. KEY RESULTS: From screening of a composite library of 3500 drugs, five drugs (when applied in a post-treatment regimen relative to stretch injury) improved both LDH and MTT responses. The effects of rifampicin were investigated in further detail. Rifampicin reduced cell necrosis and apoptosis and improved cellular bioenergetics. In a second model (stretch injury in human stem cell-derived neurons), rifampicin pretreatment attenuated LDH release, protected against the loss of neurite length and maintained neuron-specific class III β-tubulin immunoreactivity. CONCLUSIONS AND IMPLICATIONS: We conclude that the current model is suitable for medium-throughput screening to identify compounds with neuroprotective potential. Rifampicin, when applied either in pre- or post-treatment, improves the viability of neurons subjected to stretch injury and protects against neurite loss. Rifampicin may be a candidate for repurposing for the therapy of traumatic brain injury. LINKED ARTICLES: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc.
Authors: Patrick M Kochanek; Travis C Jackson; Nikki Miller Ferguson; Shaun W Carlson; Dennis W Simon; Erik C Brockman; Jing Ji; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Anthony E Kline; Philip E Empey; Robert S B Clark; Edwin K Jackson; C Edward Dixon Journal: Semin Neurol Date: 2015-02-25 Impact factor: 3.420
Authors: Celia Chao; John R Zatarain; Ye Ding; Ciro Coletta; Amy A Mrazek; Nadiya Druzhyna; Paul Johnson; Haiying Chen; Judy L Hellmich; Antonia Asimakopoulou; Kazunori Yanagi; Gabor Olah; Petra Szoleczky; Gabor Törö; Fredrick J Bohanon; Minal Cheema; Rachel Lewis; David Eckelbarger; Akbar Ahmad; Katalin Módis; Ashley Untereiner; Bartosz Szczesny; Andreas Papapetropoulos; Jia Zhou; Mark R Hellmich; Csaba Szabo Journal: Mol Med Date: 2016-05-16 Impact factor: 6.354
Authors: Matthew L Pearn; Ingrid R Niesman; Junji Egawa; Atsushi Sawada; Angels Almenar-Queralt; Sameer B Shah; Josh L Duckworth; Brian P Head Journal: Cell Mol Neurobiol Date: 2016-07-06 Impact factor: 5.046
Authors: Won Seog Chong; Chang Lim Hyun; Min Kyu Park; Jeong Min Park; Hyun-Ouk Song; Taejin Park; Young Su Lim; Choon Kyu Cho; Po Soon Kang; Hee Uk Kwon Journal: Korean J Anesthesiol Date: 2012-02-20
Authors: Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies Journal: Nucleic Acids Res Date: 2015-10-12 Impact factor: 16.971
Authors: Patrick M Kochanek; Travis C Jackson; Ruchira M Jha; Robert S B Clark; David O Okonkwo; Hülya Bayır; Samuel M Poloyac; Amy K Wagner; Philip E Empey; Yvette P Conley; Michael J Bell; Anthony E Kline; Corina O Bondi; Dennis W Simon; Shaun W Carlson; Ava M Puccio; Christopher M Horvat; Alicia K Au; Jonathan Elmer; Amery Treble-Barna; Milos D Ikonomovic; Lori A Shutter; D Lansing Taylor; Andrew M Stern; Steven H Graham; Valerian E Kagan; Edwin K Jackson; Stephen R Wisniewski; C Edward Dixon Journal: J Neurotrauma Date: 2019-02-01 Impact factor: 5.269
Authors: Patrick M Kochanek; C Edward Dixon; Stefania Mondello; Kevin K K Wang; Audrey Lafrenaye; Helen M Bramlett; W Dalton Dietrich; Ronald L Hayes; Deborah A Shear; Janice S Gilsdorf; Michael Catania; Samuel M Poloyac; Philip E Empey; Travis C Jackson; John T Povlishock Journal: Front Neurol Date: 2018-08-07 Impact factor: 4.003